Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers Health (HIMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...